These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33837299)

  • 1. Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin.
    Karsa M; Kosciolek A; Bongers A; Mariana A; Failes T; Gifford AJ; Kees UR; Cheung LC; Kotecha RS; Arndt GM; Haber M; Norris MD; Sutton R; Lock RB; Henderson MJ; Somers K
    Br J Cancer; 2021 Jul; 125(1):55-64. PubMed ID: 33837299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ; Schneider P; Pieters R; Stam RW
    Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer.
    Liu X; Wang W; Yin Y; Li M; Li H; Xiang H; Xu A; Mei X; Hong B; Lin W
    Invest New Drugs; 2019 Dec; 37(6):1166-1176. PubMed ID: 30825105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.
    Zhao H; Shi P; Deng M; Jiang Z; Li Y; Kannappan V; Wang W; Li P; Xu B
    Oncotarget; 2016 Dec; 7(51):85515-85528. PubMed ID: 27888802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative oncology approach to drug repurposing in osteosarcoma.
    Parrales A; McDonald P; Ottomeyer M; Roy A; Shoenen FJ; Broward M; Bruns T; Thamm DH; Weir SJ; Neville KA; Iwakuma T; Fulbright JM
    PLoS One; 2018; 13(3):e0194224. PubMed ID: 29579058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA-approved disulfiram as a novel treatment for aggressive leukemia.
    Karsa M; Xiao L; Ronca E; Bongers A; Spurling D; Karsa A; Cantilena S; Mariana A; Failes TW; Arndt GM; Cheung LC; Kotecha RS; Sutton R; Lock RB; Williams O; de Boer J; Haber M; Norris MD; Henderson MJ; Somers K
    J Mol Med (Berl); 2024 Apr; 102(4):507-519. PubMed ID: 38349407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer.
    Zou P; Chen M; Ji J; Chen W; Chen X; Ying S; Zhang J; Zhang Z; Liu Z; Yang S; Liang G
    Oncotarget; 2015 Nov; 6(34):36505-21. PubMed ID: 26431378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of the Glutathione, Thioredoxin, and Nrf2 Antioxidant Systems in Head and Neck Cancer.
    Roh JL; Jang H; Kim EH; Shin D
    Antioxid Redox Signal; 2017 Jul; 27(2):106-114. PubMed ID: 27733046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.
    Fiskus W; Saba N; Shen M; Ghias M; Liu J; Gupta SD; Chauhan L; Rao R; Gunewardena S; Schorno K; Austin CP; Maddocks K; Byrd J; Melnick A; Huang P; Wiestner A; Bhalla KN
    Cancer Res; 2014 May; 74(9):2520-32. PubMed ID: 24599128
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Floros KV; Cai J; Jacob S; Kurupi R; Fairchild CK; Shende M; Coon CM; Powell KM; Belvin BR; Hu B; Puchalapalli M; Ramamoorthy S; Swift K; Lewis JP; Dozmorov MG; Glod J; Koblinski JE; Boikos SA; Faber AC
    Cancer Res; 2021 Apr; 81(7):1896-1908. PubMed ID: 33483374
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
    Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
    Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
    Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
    Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis.
    Hou GX; Liu PP; Zhang S; Yang M; Liao J; Yang J; Hu Y; Jiang WQ; Wen S; Huang P
    Cell Death Dis; 2018 Jan; 9(2):89. PubMed ID: 29367724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rheumatoid arthritis drug auranofin exerts potent anti-lymphoma effect by stimulating TXNRD-mediated ROS generation and inhibition of energy metabolism.
    Yang M; Liu J; Li J; Wen S; Hu Y; Lu W; Liu J; Huang P; Liu P
    Redox Biol; 2024 Sep; 75():103245. PubMed ID: 38909408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Menin‑MLL inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells.
    Kato I; Kasukabe T; Kumakura S
    Int J Oncol; 2020 Oct; 57(4):1057-1071. PubMed ID: 32945449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib.
    Morishita T; Hayakawa F; Sugimoto K; Iwase M; Yamamoto H; Hirano D; Kojima Y; Imoto N; Naoe T; Kiyoi H
    Oncotarget; 2016 Aug; 7(35):56241-56252. PubMed ID: 27494842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo.
    Fan C; Zheng W; Fu X; Li X; Wong YS; Chen T
    Cell Death Dis; 2014 Apr; 5(4):e1191. PubMed ID: 24763048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antineoplastic effects of auranofin in canine lymphoma cells.
    Zhang H; Rose BJ; Pyuen AA; Thamm DH
    BMC Cancer; 2018 May; 18(1):522. PubMed ID: 29724201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.
    Sison EA; Rau RE; McIntyre E; Li L; Small D; Brown P
    Br J Haematol; 2013 Mar; 160(6):785-97. PubMed ID: 23294096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting non-oncogene ROS pathway by alantolactone in B cell acute lymphoblastic leukemia cells.
    Xu X; Huang L; Zhang Z; Tong J; Mi J; Wu Y; Zhang C; Yan H
    Life Sci; 2019 Jun; 227():153-165. PubMed ID: 31004657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.